DLX3 Antibody

Code CSB-PA002153
Size US$167
  • Western Blot analysis of 293 cells using Dlx-3 Polyclonal Antibody
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No. O60479
Target Names DLX3
Alternative Names AI4 antibody; Distal less homeo box 3 antibody; DLX 3 antibody; Dlx3 antibody; DLX3 distalless homeobox 3 antibody; DLX3_HUMAN antibody; Homeobox protein DLX 3 antibody; Homeobox protein DLX-3 antibody; Homeobox protein Dlx3 antibody; TDO antibody
Raised in Rabbit
Species Reactivity Human,Mouse
Immunogen Synthesized peptide derived from the Internal region of Human Dlx-3.
Immunogen Species Homo sapiens (Human)
Conjugate Non-conjugated
Isotype IgG
Purification Method The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Form Liquid
Tested Applications WB, IHC, ELISA
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:2000
IHC 1:100-1:300
ELISA 1:40000
Protocols Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
ELISA Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function Likely to play a regulatory role in the development of the ventral forebrain. May play a role in craniofacial patterning and morphogenesis.
Gene References into Functions
  1. our studies demonstrate that DLX3 physically interacts with GCM1 and inhibits its transactivation activity, suggesting that DLX3 and GCM1 may form a complex to functionally regulate placental cell function through modulation of target gene expression. PMID: 28515447
  2. Our research of DLX3 mutation protecting aging-related bone loss opens the possibility of its therapeutic potential in bone regeneration and bone loss disease. PMID: 27924851
  3. DLX3 expression specifically modulates regulatory networks such as Wnt signaling, phosphatase activity and cell adhesion. PMID: 28186503
  4. Novel de novo mutation of DLX3 significantly decreases the proliferation rate and inhibits the odontogenic differentiation and mineralization of hDPCs, suggesting that this novel mutation of DLX3 can influence the dentinogenesis in TDO syndrome. PMID: 28135572
  5. DLX3 regulates bone marrow mesenchymal stem cell proliferation through H19/miR-675 axis. PMID: 28963438
  6. Data establish the DLX3-p53 interplay as a major regulatory axis in epidermal differentiation and suggest that DLX3 is a modulator of skin carcinogenesis. PMID: 26522723
  7. Identify a novel cis-acting sequence (-369 to -320) at the placental growth factor promoter, which was critical for mediating the basal and DLX3/GCM1-dependent PGF promoter activities. PMID: 27996093
  8. We showed that the supplementation of the osteogenic differentiation medium with PTHrP inhibited the alkaline phosphatase activity and the expression of the transcription factor DLX3, but the depletion of PTHrP did not support the differentiation of DFCs.We showed that SUFU (Suppressor Of Fused Homolog) was not regulated during the osteogenic differentiation in DFCs PMID: 27368119
  9. we identified a recurrent 2-bp deletion in the DLX3 gene in a new family and described their mild clinical phenotype related to the DLX3 mutation. PMID: 26762616
  10. genetic analysis revealed a novel de novo missense mutation c.533A>G (p.Q178R) in the conserved homeodomain of the DLX3 gene. This DLX3 mutation is the sixth causative mutation for TDO to be identified so far. PMID: 26104267
  11. ER-alpha regulates the osteoblast differentiation through modulation of Dlx3 expression and/or interaction with Dlx3. PMID: 26674964
  12. Results suggest that Dlx3 is a novel target of PKA, and that PKA mediates BMP signaling during osteoblast differentiation, at least in part, by phosphorylating Dlx3 and modulating its stability and function. PMID: 24924519
  13. rs2278163 SNP of DLX3 might be associated with dental caries susceptibility in Japanese children. T and C alleles of rs2278163 SNP may potentially be involved in caries susceptibility and caries protection respectively. PMID: 25247779
  14. In conclusion, results of our study suggest that the NOTCH-signaling pathway, which is activated during the osteogenic differentiation of DFCs. PMID: 24321094
  15. DLX3 orchestrates the expression of multiple regulators of trophoblast differentiation and that expression of these regulatory genes is abnormal in fetal growth restriction. PMID: 23831639
  16. DLX3 stimulates osteogenic differentiation via BMP2 dependent pathway. PMID: 22107079
  17. Increased DLX3 expression in idiopathic fetal growth restricion (FGR) may contribute to trophoblast dysfunction observed in FGR. PMID: 22113468
  18. DLX3 acts upstream of syncytin, 3beta-hydroxysteroid dehydrogenase, and the human gonadotropin beta-subunit to play a regulatory role in villous cytotrophoblast differentiation. PMID: 21802725
  19. DLX3 homeodomain mutations cause tricho-dento-osseous syndrome with novel phenotypes PMID: 21252474
  20. In cells expressing equal amounts of mutant and wild-type DLX3, deltaNp63alpha protein level was efficiently regulated, implying that heterozygosity at the DLX3 locus protects tricho-dento-osseous patients from severe p63-associated skin defects. PMID: 21520071
  21. SUMOylation of DLX3 by SUMO1 promotes its transcriptional activity. PMID: 21268066
  22. Nuclear expression for DLX3 was observed in villous cytotrophoblasts, syncytiotrophoblast and extravillous cytotrophoblast in the proximal regions of the cytotrophoblast cell columns in first trimester placental tissues. PMID: 20542333
  23. A genetic investigation revealed a de-novo mutation in the DLX3 gene on chromosome 17q21. PMID: 20151948
  24. Enamel hardness with 2-bp del in DLX3 was about 53% normal enamel hardness. Mutant enamel thickness was about 50% normal thickness. Calcium level in enamel with 2-bp del was slightly decreased; magnesium level was slightly increased, compared to normal. PMID: 19608154
  25. AP-2 gamma and Dlx 3, together with an additional transcription factor(s) that are conserved between humans and mice, are required for trophoblast-specific expression of 3 beta-HSD VI. PMID: 11773066
  26. Genomic structure and functional control of the Dlx3-7 bigene cluster PMID: 11792834
  27. Overexpression of C/EBP beta was sufficient to increase basal expression of a Dlx3 reporter gene in a dose-dependent manner. PMID: 14670999
  28. results suggest that DLX3 gene is important in bone formation and/or homeostasis of the appendicular skeleton PMID: 15454107
  29. This is the first report of a mutation within the homeodomain of DLX3. PMID: 15666299
  30. p63 and Dlx play central roles in embryonic patterning and regulation of different developmental processes, and their mutations have been associated with ectodermal dysplasias [review] PMID: 16187309
  31. mutation has positive effects on bone density throughout life PMID: 16301156
  32. DLX-3 gene expression was increased in dental follicle cells during osteogenic differentiation. PMID: 16467978
  33. Smad6 appears to functionally interact with Dlx3, altering the ability of Dlx3 to bind target gene promoters. PMID: 16687405
  34. gene defect of trichodentoosseous syndrome has been localized only in the DLX3 gene PMID: 17559453
  35. Results show that differential DLX3 methylation could be a new epigenetic marker for genotypic B-cell leukemia subgroup with high-risk features. PMID: 17611665
  36. Carboxy-terminus of the DLX3 protein is critical in determining its function during development in hair, tooth, and bone. PMID: 18203197
  37. The identified mutation was c.561_562delCT mutation in the DLX3 gene. This study clearly showed that the c.561_562delCT mutation had not only enamel defects, but also other clinical phenotypes resembling those of TDO syndrome. PMID: 18362318
  38. DLX3(TDO) has a dominant negative effect on DLX3(WT) transcriptional activity PMID: 18492670
  39. Dlx3 triggers p63 protein degradation by a proteasome-dependent pathway. PMID: 19282665
  40. results suggest that a serine residue in the homeodomain of the mouse Dlx3 protein can be directly phosphorylated by a protein kinase C-dependent pathway, which affects the DNA binding activity of Dlx3. PMID: 11343707

Show More

Hide All

Involvement in disease Trichodentoosseous syndrome (TDO); Amelogenesis imperfecta 4 (AI4)
Subcellular Location Nucleus
Protein Families Distal-less homeobox family
Database Links

HGNC: 2916

OMIM: 104510

KEGG: hsa:1747

STRING: 9606.ENSP00000389870

UniGene: Hs.134194


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1